Illumina, Inc. $ILMN Shares Sold by Hardman Johnston Global Advisors LLC

Key Points

• Hardman Johnston Global Advisors trimmed its Illumina stake by 19.2% in Q4, selling 30,148 shares and leaving it with 127,236 shares worth about $16.69 million.
• SVP Patricia Leckman sold 2,370 shares at an average price of $116.18, a 12.68% reduction in her personal holdings, indicating insider selling activity.
• Illumina posted an earnings beat (EPS $1.35 vs. $1.26) and $1.16B in revenue, set FY2026 guidance of 5.05–5.20 EPS, and trades around $121 with an average analyst target near $129.69 amid mixed ratings.

Hardman Johnston Global Advisors LLC trimmed its position in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 19.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 127,236 shares of the life sciences company's stock after selling 30,148 shares during the period. Hardman Johnston Global Advisors LLC owned approximately 0.08% of Illumina worth $16,688,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Board of the Pension Protection Fund acquired a new position in Illumina during the fourth quarter worth $26,000. Flagship Harbor Advisors LLC acquired a new position in Illumina during the fourth quarter worth $33,000. V Square Quantitative Management LLC acquired a new position in Illumina during the fourth quarter worth $34,000. Quent Capital LLC acquired a new stake in shares of Illumina in the third quarter valued at $29,000. Finally, Quarry LP acquired a new stake in shares of Illumina in the third quarter valued at $32,000. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Illumina news, SVP Patricia Leckman sold 2,370 shares of the firm's stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $116.18, for a total value of $275,346.60. Following the sale, the senior vice president directly owned 16,321 shares in the company, valued at $1,896,173.78. This trade represents a 12.68% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.17% of the stock is currently owned by corporate insiders.

Illumina Price Performance

Illumina stock opened at $120.93 on Monday. Illumina, Inc. has a 1-year low of $69.83 and a 1-year high of $155.53. The company has a debt-to-equity ratio of 0.55, a current ratio of 2.08 and a quick ratio of 1.72. The stock has a market cap of $18.37 billion, a PE ratio of 22.19, a P/E/G ratio of 2.32 and a beta of 1.49. The stock's fifty day moving average is $123.95 and its two-hundred day moving average is $123.65.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its quarterly earnings results on Thursday, February 5th. The life sciences company reported $1.35 earnings per share for the quarter, beating analysts' consensus estimates of $1.26 by $0.09. Illumina had a return on equity of 31.04% and a net margin of 19.57%.The company had revenue of $1.16 billion for the quarter, compared to analysts' expectations of $1.10 billion. During the same period last year, the firm earned $0.95 earnings per share. Illumina's quarterly revenue was up 5.0% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. On average, sell-side analysts expect that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently issued reports on the company. Weiss Ratings reiterated a "hold (c-)" rating on shares of Illumina in a research note on Monday, December 29th. UBS Group reiterated a "neutral" rating and issued a $135.00 price objective on shares of Illumina in a research note on Friday, February 6th. Wall Street Zen upgraded Illumina from a "buy" rating to a "strong-buy" rating in a research note on Saturday, February 14th. Piper Sandler reduced their price objective on Illumina from $195.00 to $170.00 and set an "overweight" rating on the stock in a research note on Monday, February 9th. Finally, JPMorgan Chase & Co. reduced their price objective on Illumina from $130.00 to $120.00 and set a "neutral" rating on the stock in a research note on Friday, February 6th. Six research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, Illumina currently has an average rating of "Hold" and an average target price of $129.69.

Illumina News Roundup

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Analysts highlight Illumina’s strong earnings-surprise history and say the company currently has the characteristics that make another quarterly beat likely — a bullish near-term earnings catalyst that can support the stock ahead of the April 30 report. Will Illumina (ILMN) Beat Estimates Again in Its Next Earnings Report? Zacks: Will Illumina (ILMN) Beat Estimates Again?
• Neutral Sentiment: Illumina confirmed it will report Q1 2026 results after the close on Thursday, April 30, with a management conference call scheduled — a clear near-term event that could drive volatility depending on revenue/guide vs. expectations. Illumina to Announce First Quarter 2026 Financial Results
• Neutral Sentiment: Market coverage notes recent share-price strength (outperformance since Oct‑2025) but also that Illumina still lags broader market measures on some timeframes — useful context for momentum and relative-performance trades. MarketWatch: Illumina stock rises, still underperforms market
• Neutral Sentiment: A valuation/peer piece compares Illumina to Regeneron as potential value plays in the biomedical/genetics space — useful for investors weighing sector alternatives but not an immediate directional catalyst. REGN or ILMN: Which Is the Better Value Stock Right Now?
• Negative Sentiment: A Seeking Alpha analysis argues that competitive threats (new platforms, pricing pressure) are an ongoing headwind and may already be reflected in the stock — a cautionary take that can temper upside expectations and increase sensitivity to execution. Illumina: Competitive Threats Priced In
• Negative Sentiment: A recent “3 Reasons to Avoid ILMN” article outlines concerns (valuation after the run, execution/risks) that may be driving some profit‑taking and cautious positioning despite recent strong results. 3 Reasons to Avoid ILMN and 1 Stock to Buy Instead

Illumina Company Profile

Illumina, Inc NASDAQ: ILMN is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company's product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.